Range Nuclear Renaissance ETF vs Nuwellis Inc — how do they compare? Range Nuclear Renaissance ETF trades at $61.26 (market cap $698.21M), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Range Nuclear Renaissance ETF is far larger — about 317.4× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 57,444). Which is the better fit depends on your goals — on Pluang, investors hold Range Nuclear Renaissance ETF for 18 Days and Nuwellis Inc for 26 Days on average.
| NUKZ | NUWE | |
|---|---|---|
Market Cap | $698.21M | $2.20M |
Volume | 57,444 | 121,544 |
Sector | Sector/Thematic | Health |
52-Week High | $76.23 | $146.65 |
52-Week Low | $60.23 | $0.68 |
Typical Hold Time | 18 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.
Read more on NUKZ →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →